Home

MICHAEL POWELL

CIK 1202793 · last filed 2026-06-10

MICHAEL POWELL is a corporate insider who has filed 58 SEC Form 4 insider transactions across 14 companies since 2007. The most recent filing, for BCAX, was dated Jun 10, 2026. Across all open-market trades the lifetime net is +$87.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $74.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$74.09M

Companies

14

Total Filings

58

Lifetime Open-Market Net

$87.04M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BCAX Director — $26.88 — $0 2 2026-06-10
GRTX Director — $17.60 — $0 5 2023-06-16
Checkmate Pharmaceuticals, Inc. (CMPI) Delisted Director — $10.50 — $0 4 2022-05-31
VERA 10%+ Owner 2,187,504 $33.32 $72.89M $32.00M 1 2021-05-18
NXTC 10%+ Owner 222,655 $5.42 $1.21M $27.56M 1 2019-11-19
SYNLOGIC, INC. (SYBX) Delisted Director 38,331 $0.69 $26.4K $0 5 2019-06-07
Iterum Therapeutics plc (ITRM) Delisted 10%+ Owner 81,768 $0.03 $2.5K $26.00M 1 2018-05-30
SYNLOGIC, INC. (MIRN) Delisted Director 2,117,669 — — $6.00M 2 2016-09-06
HUMANIGEN, INC (KBIO) Delisted 10%+ Owner 39,637 — — $0 1 2013-02-07
Trius Therapeutics Inc (TSRX) Delisted Director 9,302 — — $3.98M 7 2012-03-27
Anthera Pharmaceuticals Inc (ANTH) Delisted 10%+ Owner 51,542 — — -$1.09M 1 2012-01-03
Orexigen Therapeutics, Inc. (OREX) Delisted Director 3,236 — — -$22.41M 13 2011-06-06
Molecular Templates, Inc. (THLD) Delisted Director — — — $0 2 2008-05-14
ANESIVA, INC. (ANSV) Delisted Director 3,703,769 — — $15.00M 5 2008-05-12

Recent Filings

58 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-10 BCAX Grant (A) — $0 EDGAR
2025-06-10 BCAX Grant (A) — $0 EDGAR
2023-06-16 GRTX Grant (A) — $0 EDGAR
2022-06-16 GRTX Grant (A) — $0 EDGAR
2022-05-31 Checkmate Pharmaceuticals, Inc. (CMPI) Delisted Disp (D) — $0 EDGAR
2021-08-10 Checkmate Pharmaceuticals, Inc. (CMPI) Delisted Grant (A) — $0 EDGAR
2021-06-21 Checkmate Pharmaceuticals, Inc. (CMPI) Delisted Grant (A) — $0 EDGAR
2021-06-17 GRTX Grant (A) — $0 EDGAR
2021-05-18 VERA Mixed +11,659,104 $32.00M EDGAR
2020-11-12 Checkmate Pharmaceuticals, Inc. (CMPI) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 58
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.